Article

Exogenous and Endogenous Glucocorticoids in Rheumatic Diseases

Charité University Medicine Berlin and Berlin-Brandenburg Center of Regenerative Therapies, Berlin, Germany.
Arthritis & Rheumatology (Impact Factor: 7.87). 01/2011; 63(1):1-9. DOI: 10.1002/art.30070
Source: PubMed
Download full-text

Full-text

Available from: Rainer H Straub, Oct 22, 2014
0 Followers
 · 
87 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoids (GCs) provide a powerful and widely used anti-inflammatory and disease-modifying therapy for rheumatoid arthritis (RA). However, concerns about adverse effects are driving efforts to find 'safer' GC or GC analogues. One novel approach has been to change the timing of GC delivery, targeting the early hours of the morning to suppress the observed circadian peak in interleukin-6 (IL-6). The CAPRA-1 study has shown that this produces a clinically useful beneficial improvement in morning stiffness and mechanistic studies have shown that this correlates with a strong suppression of the IL-6 early morning peak. With no obvious additional adverse reactions, this improvement in the therapeutic ratio offers additional treatment options in RA, and perhaps in other inflammatory diseases that show circadian variation in symptoms.
    Therapeutic advances in musculoskeletal disease 06/2012; 4(3):159-66. DOI:10.1177/1759720X12441274
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of corticosteroids on spinal fusion healing has not yet been determined. To evaluate the effect of corticosteroids on lumbar spinal fusion we designed a randomized, placebo-controlled animal study using high-dose methylprednisolone sodium succinate, which is widely used in patients with spinal cord injury who are undergoing spinal fusion. Two groups of 18 rabbits underwent a postero-lateral fusion at L5-L6 with autologous bone graft. After surgery, the animals were assigned to receive: (a) methylprednisolone sodium succinate 30 mg/kg over 15 min, followed by an intravenous infusion of 5.4 mg/kg/h for 23 h, or (b) normal saline in the same volume. Animals were killed 8 weeks after surgery; the presence of fusion was analyzed by use of two different methods: a manual palpation test and an antero-posterior radiograph. Both groups of animals were comparable in weight. Fusion was achieved in 5/18 rabbits (27.8%) in the methylprednisolone group and in 9/18 animals (50%) in the control group (p = 0.17). In a lumbar posterolateral fusion rabbit model, high-dose methylprednisolone sodium succinate reduced the success of lumbar fusion; however, our data did not reach statistical significance.
    Journal of Orthopaedic Science 04/2011; 16(4):439-42. DOI:10.1007/s00776-011-0061-3 · 1.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Microparticles (MPs) are small membrane-bound vesicles that display proinflammatory and prothrombotic properties. These particles can be released by macrophages stimulated by ligands of the Toll-like receptors (TLRs) in a process that depends on nitric oxide (NO) production. Since sex hormones can modulate macrophage responses, we investigated the effects of progesterone and estradiol on macrophage particle release in vitro, comparing the responses with those induced by the glucocorticoid dexamethasone. As a model system for particle release, RAW 264.7 cells were stimulated in vitro with poly(I:C), a ligand of TLR3. Microparticles were measured by flow cytometry, while NO was measured by the Griess reaction. As the results of these studies showed, progesterone but not estradiol can block particle release by RAW264.7 cells treated with poly(I:C); dexamethasone was also active. Furthermore, while progesterone and dexamethasone inhibited NO production under the same culture conditions, neither agent blocked the production of particles stimulated by the NO donors dipropylenetriamine NONOate {(z)-1-[N-(3-aminopropyl)-N-(3-ammoniopropyl)amino] diazen-1-ium-1,2-diolate} and (z)-1-[(2-aminoethyl)-N-(2-ammonioethyl)amino] diazen-1-ium-1,2-diolate. Studies using RU486 to assess the role of hormone receptors indicated that while this agent blocked the inhibition of particle and NO production by dexamethasone, it did not affect the inhibition by progesterone. Together, these results indicate that progesterone but not estradiol can inhibit particle release by stimulated macrophages and suggest a mechanism that may contribute to the immunomodulatory effects of this sex hormone.
    Clinical and vaccine Immunology: CVI 06/2011; 18(9):1420-6. DOI:10.1128/CVI.05110-11 · 2.37 Impact Factor